Ocugen to Participate in Upcoming May Scientific and Investor Conferences

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific and investor conferences in May 2026.

Inherited and Rare Retinal Diseases SessionModerators: Kourous A. Rezaei, MD and Rishi P. Singh, MD, FASRSLocation: Grand BallroomDate: Thursday, May 14, 2026Time: 10:31 am – 11:10 a.m. EDT

Location: VirtualDate: Tuesday, May 26, 2026Time: 10:30 am – 10:55 a.m. EDT

A webcast of the Stifel presentation will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visitInvestors | Ocugen, Inc.

AboutOcugen,Inc.Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more atwww.ocugen.comand follow us onXandLinkedIn.

CautionaryNoteonForward-LookingStatementsThispressreleasecontainsforward-lookingstatementswithinthemeaningofThePrivateSecuritiesLitigationReformActof1995,including,butnot limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatoryfilingsandanticipateddevelopmenttimelines,whicharesubjecttorisksanduncertainties.Wemay,insomecases,usetermssuchas“predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,”or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including,butnotlimitedto,therisksthatpreliminary,interimandtop-lineclinicaltrialresultsmaynotbeindicativeof,andmaydifferfrom,finalclinical data;thatunfavorablenewclinicaltrialdatamayemergeinongoingclinicaltrialsorthroughfurtheranalysesofexistingclinicaltrialdata;thatearlier non-clinicalandclinicaldataandtestingofmaynotbepredictiveoftheresultsorsuccessoflaterclinicaltrials;andthatthatclinicaltrialdataare subjecttodifferinginterpretationsandassessments,includingbyregulatoryauthorities. Theseand otherrisks anduncertaintiesare more fully describedinourperiodicfilingswiththeSecuritiesandExchangeCommission(SEC), includingtheriskfactorsdescribedinthesectionentitled“Risk Factors”inthequarterlyandannualreportsthatwefilewiththeSEC.Anyforward-lookingstatementsthatwemakeinthispressreleasespeakonlyas ofthedateofthispressrelease.Exceptasrequiredbylaw,weassumenoobligationtoupdateforward-lookingstatementscontainedinthispress release whether as a result of new information, future events, or otherwise, after the date of this press release.